The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review

ISSN: 1875-6190 (Online)
ISSN: 1570-159X (Print)

Volume 15, 8 Issues, 2017

Download PDF Flyer

Current Neuropharmacology

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 72nd of 256 in Neuroscience
  • 24th of 253 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

T.E. Salt
University College London
Institute of Ophthalmology
London EC1V 9EL

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.753
5 - Year: 3.478

The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review

Current Neuropharmacology, 12(5): 444-461.

Author(s): Gianluca Serafini, Robert H. Howland, Fabiana Rovedi, Paolo Girardi and Mario Amore.

Affiliation: Department of Neurosciences, Mental Health and Sensory Organs – Sant’Andrea Hospital, Sapienza University of Rome, Via di Grottarossa 1037, 00189, Rome, Italy.


Background: At least 10-20% of the patients suffering from depression meet criteria for treatment-resistant depression (TRD). In the last decades, an important role of glutamate in mood modulation has been hypothesized and ketamine, a non noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptors, has been demonstrated to be effective in both MDD and TRD. However, concerns emerged about the optimal dosage, and frequency of administration of this treatment.

Methods: aiming to systematically review the current literature focusing on the main pharmacological properties and impact of ketamine in TRD, a detailed literature search in PubMed/Medline and ScienceDirect databases was conducted. Twenty-four manuscripts including a total of 416 patients fulfilled inclusion criteria.

Results: Most studies demonstrated that the NMDA antagonist ketamine has rapid antidepressant effects in TRD patients, confirming the active role of glutamate in the pathophysiology of this complex condition. Ketamine has been demonstrated to be rapidly effective and was associated with a significant clinical improvement in depressive symptoms within hours after administration. Also, ketamine was also found to be effective in reducing suicidality in TRD samples.

Limitations: The long-term efficacy of ketamine has not been investigated by most studies. The psychotomimetic properties may complicate the application of this pharmacological agent.

Conclusions: Ketamine may be considered a valid and intriguing antidepressant option for the treatment of TRD. Further studies are needed to evaluate its long-term antidepressant efficacy in patients with TRD.


Antidepressant effect, ketamine, NMDA receptors, pharmacological properties, treatment-resistant depression.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 12
Issue Number: 5
First Page: 444
Last Page: 461
Page Count: 18
DOI: 10.2174/1570159X12666140619204251
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science